Novo Nordisk's Two-Front Storm: A Legal Escalation and a Pricing Cliff

Novo Nordisk's record profit and raised outlook are overshadowed by a shareholder lawsuit over CagriSema and looming US Medicare price cuts.

The numbers coming out of Bagsværd this week told one story — a record operating profit, a raised outlook, and an obesity franchise that keeps churning out prescriptions. The share price told quite another. And now, a US federal judge has added a third narrative that investors can't ignore: a shareholder lawsuit that just cleared a critical legal hurdle.

A Legal Shadow Over CagriSema

The litigation stems from a setback that has haunted Novo Nordisk since February. Patients on CagriSema lost an average of 20.2 percent of their body weight in late-stage trials — respectable by most standards, but short of the 23.6 percent posted by Eli Lilly's Tirzepatid. The drug missed its non-inferiority target, and the market has been punishing the company for it ever since.

CEO Mike Doustdar has pushed back against that reading, telling CNBC that investors were too harsh on the data and that additional studies would paint a fuller picture. But this week, a US federal judge allowed parts of a shareholder lawsuit to proceed, ruling that investors had plausibly argued the company's statements on CagriSema's tolerability and trial design may have been misleading.

The ruling doesn't establish wrongdoing — it simply opens the door to discovery. But that's precisely the problem for Novo. The case could keep the CagriSema question in headlines for months, possibly stretching deep into 2027. A company spokesperson dismissed the allegations as unfounded and vowed a vigorous defense.

The Price Mechanic That Looms Larger Than Any Trial

The legal noise is landing at an awkward moment for another reason: the US pricing environment is about to change in ways that could reshape Novo's entire margin structure.

Since July 1, 2026, eligible Medicare patients have paid just $50 a month for GLP-1 therapies under an interim arrangement. That's the gentle prelude. On January 1, 2027, a negotiated Medicare price of $274 per month for semaglutide kicks in — a 71 percent reduction in the US price for the drug's active ingredient.

That's the number investors are really wrestling with. Can volume growth from the oral Wegovy pill — which has already surpassed 5 million US prescriptions — offset a price cut of that magnitude? The market's skepticism is baked into the current valuation.

Strong Earnings, Tepid Reception

The operational picture, on its own, looks solid. On August 4, Novo Nordisk reported adjusted operating profit of 33.4 billion Danish kroner, comfortably beating the 28.74 billion kroner analysts had penciled in. Management also lifted its full-year guidance, narrowing the expected growth range to between 0 and minus 6 percent, an improvement from the previous floor of minus 12 percent.

None of that moved the needle. The stock fell 5.85 percent on Tuesday to €38.44, extending the seven-day slide to 14.80 percent. The culprit, at least initially, was the July 31 failure of the Phase 3 ZEUS trial for the heart drug Ziltivekimab — a setback that erased roughly $30 billion in market value and continues to overshadow the operational wins in the obesity segment.

The market cap now stands at €180.57 billion, and the shares trade nearly 30 percent below their 52-week high of €54.86, hit back in January. The 14-day RSI sits at 33.6, flirting with oversold territory, while annualized volatility of 38.33 percent reflects just how jittery trading has become.

A Chart That Offers Little Comfort

Technical analysts see few reasons for optimism. The stock is trading below both its 50-day moving average of €40.95 and its 200-day average of €40.32 — a configuration that historically signals further downside risk. Should Eli Lilly release strong competitive data, a retest of the 52-week low of €30.25 can't be ruled out.

The competitive threat is real and growing. The FDA approved Eli Lilly's oral competitor Foundayo (orforglipron) on April 1, 2026, and unlike Novo's oral semaglutide, it doesn't carry strict fasting requirements. The ZEUS failure has also narrowed Novo's ability to diversify beyond its core obesity franchise, leaving it more exposed to a single product category at precisely the moment pricing pressure intensifies.

What Investors Are Waiting To Hear

Wednesday's earnings call is shaping up as the immediate focal point. Investors want to know how management plans to protect margins through the pricing transition — whether internal efficiency gains can cushion the impact of the $50 program now and the $274 cap later.

The bull case rests on the oral pill's momentum and the raised profit guidance as evidence that the company can absorb the near-term pain. Bulls also point to the stock sitting 27.07 percent above its 52-week low of €30.25 as a potential stabilization zone, with the oversold RSI suggesting a bounce could materialize on positive signals from the call. Operating profit grew 11 percent year over year, underscoring that the core business remains resilient despite the Ziltivekimab disappointment.

The bear case is equally straightforward: a damaged chart, intensifying competition, and now a legal overhang that could drag on for years. The discovery process in the shareholder suit is expected to surface new details about internal communications and how CagriSema data was presented to investors — none of which will make the search for a floor any easier.

For now, the stock is caught between a pricing cliff that arrives in January and a courtroom that could keep generating headlines well beyond it. The reclaiming of the €40.95 level would be the first technical signal that buyers are returning. The next fundamental test comes on January 1, 2027, when the negotiated Medicare price takes effect — the day the market's real question about Novo's margin structure gets its answer.